Beijing Science Sun Pharmaceutical Full Year 2024 Earnings: CN¥0.14 loss per share (vs CN¥0.21 profit in FY 2023)

Beijing Science Sun Pharmaceutical (SZSE:300485) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥416.5m (down 13% from FY 2023).
• Net loss: CN¥68.9m (down by 167% from CN¥102.9m profit in FY 2023).
• CN¥0.14 loss per share (down from CN¥0.21 profit in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Science Sun Pharmaceutical's share price is broadly unchanged from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Beijing Science Sun Pharmaceutical.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.